About Dare Bioscience Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.darebioscience.com/
Frequently Asked Questions
What is the 52-week range for DARE?
The 52-week high is $3.78 and the 52-week low is $0.69.
What is the P/E ratio for DARE?
The P/E ratio data is currently unavailable.
What is the dividend yield for DARE?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -373.17%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -804.36%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 9.70.
Analyst Recommendation Trends
Wall Street analyst consensus for DARE over the last few months:
Latest DARE News
Daré Bioscience Says It Received Nasdaq Minimum Bid Price Deficiency Notice, Has Until March 29, 2027 To Regain Compliance
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001401914/000140191426000052/dare-20260928.htm
Dare Bioscience stock rises after receiving HPV treatment patent
Investing.com -- Dare Bioscience Inc (NASDAQ:DARE) shares rose 2.8% on Monday following the announcement that the company received a new U.S. patent for its HPV treatment program.
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection DARE-HPV Phase 2 study underway with topline results expected in 2027; program supported by approximately $10 million in non-dilutive ARPA-H funding and a $2.0 million NIAID award DARE-HPV is designed to address a major treatment gap for the millions of U.S. women who experience high-risk HPV infection each year, for which there is currently
Daré Bioscience Receives U.S. Patent For Its Pharmaceutical Compositions Formulated For Topical Application Comprising Lopinavir, Ritonavir To Treat Cervical Pathologies
Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the issuance of
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience’s proprietary topical Sildenafil Cream, 3.6% At the 71 mg topical dose, mean maximum plasma concentration of sildenafil was approximately 187-fold lower than following a 50 mg oral dose Publication expands peer-reviewed clinical evidence supporting Daré Bioscience’s proprietary topical Sildenafil Cream formulation SAN DIEGO, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a
Daré Bioscience Announces Publication Of Results From A Phase 1 Clinical Study Evaluating Safety And Systemic Pharmacokinetics Of Topical Sildenafil Cream, 3.6%, In Healthy Adult Men In The Journal Sexual Medicine; At 71 Mg Topical Dose, Mean Maximum Plasma Concentration Of Sildenafil Was ~187-Fold Lower Than Following A 50 Mg Oral Dose
The article, titled, "An open-label, single-dose, randomized, parallel-group study of the safety and relative bioavailability of topical sildenafil cream vs oral sildenafil in healthy male adults," discusses
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
View the video webcast here SAN DIEGO, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that its pre-recorded presentation for the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here. The presentation, featuring Sabrina Martucci Johnson, President and Chief Executive
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market session. The market value of their outstanding shares is at $58.5 million. AEON Biopharma (AMEX:AEON) shares rose
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-30 | Grossman Jessica D. | +26,066 | - | - |
| 2026-06-30 | Kelley Susan L. | +23,696 | - | - |
| 2026-06-30 | Matz Gregory W | +30,805 | - | - |
| 2026-06-30 | Steele Robin Joan | +26,540 | - | - |
| 2026-06-30 | RASTETTER WILLIAM H | +38,862 | - | - |
| 2026-06-11 | Grossman Jessica D. | +10,000 | - | - |
| 2026-06-11 | Matz Gregory W | +10,000 | - | - |
| 2026-06-11 | Kelley Susan L. | +10,000 | - | - |
| 2026-06-11 | Steele Robin Joan | +10,000 | - | - |
| 2026-06-11 | RASTETTER WILLIAM H | +10,000 | - | - |
| 2026-02-18 | JOHNSON SABRINA MARTUCCI | +21,600 | - | - |
| 2026-02-18 | JOHNSON SABRINA MARTUCCI | +10,800 | - | - |
| 2026-01-30 | Haring-Layton MarDee | +49,000 | - | - |
| 2026-01-30 | JOHNSON SABRINA MARTUCCI | +172,000 | - | - |